Peregrine Pharma starts Phase 3 immunotherapy trial in lung cancer

|About: Peregrine Pharmaceuticals Inc. (PPHM)|By:, SA News Editor

Peregrine Pharmaceuticals (PPHM +2.2%) announces the initiation of a Phase 3 trial of a bavituximab/ docetaxel combo in second-line NSCLC.

OS is the primary endpoint. (PR)